key: cord-0979607-q0cml3rz
authors: Kerkar, P.G.; Naik, N.; Alexander, T.; Bahl, V.K.; Chakraborty, R.N.; Chatterjee, S.S.; Chopra, H.K.; Dani, S.I.; Deb, P.K.; Goswami, K.C.; Guha, S.; Gupta, R.; Gupta, V.; Hasija, P.K.; Jayagopal, P.B.; Justin Paul, G.; Kahali, D.; Katyal, V.K.; Khanna, N.N.; Mandal, M.; Mishra, S.S.; Mohanan, P.P.; Mullasari, A.; Mehta, S.; Pancholia, A.K.; Ray, S.; Roy, D.; Shanmugasundarm, S.; Sharma, S.; Singh, B.P.; Tewari, S.; Tyagi, S.K.; Venugopal, K.N.; Wander, G.S.; Yadav, R.; Das, M.K.
title: Cardiological Society of India: Document on Acute MI care during COVID-19()
date: 2020-05-06
journal: Indian Heart J
DOI: 10.1016/j.ihj.2020.04.009
sha: bd1f258230e485c2cdad4eac36db9849fe349d48
doc_id: 979607
cord_uid: q0cml3rz

The unprecedented and rapidly spreading Coronavirus Disease-19 (COVID-19) pandemic has challenged public health care systems globally. Based on worldwide experience, India has initiated a nationwide lockdown to prevent the exponential surge of cases. During COVID-19, management of cardiovascular emergencies like acute Myocardial Infarction (MI) may be compromised. Cardiological Society of India (CSI) has ventured in this moment of crisis to evolve a consensus document for care of acute MI. However, this care should be individualized, based on local expertise and governmental advisories.

The global Coronavirus Disease-19 pandemic is an unprecedented, rapidly spreading public health emergency with over 2.5 million cases reported worldwide and about two lakh deaths across 213 countries as on 27th April 2020 1 . To reduce person to person transmission, government of India initiated a nationwide lockdown on 25 th March 2020. Learning from worldwide experience, the Indian health care system needs to be prepared for a surge in COVID-19 patients. Reperfusion for acute myocardial infarction (AMI) by primary percutaneous coronary intervention (PPCI) or Thrombolysis, is evidence-based, time-critical, life-saving intervention that should not be neglected in the COVID-19 era. Although rare, COVID-19, like influenza, may trigger an AMI by multiple pathways 2 . Hence this document is intended to provide strategies for triage and management of patients with AMI in the time of COVID-19.

Given the paucity of adequate data, the guidance provided in this statement is based mainly on expert opinion and the best currently available published information. This guidance may change as more data and experience in managing the epidemic and non-COVID-19 patients become available in this rapidly evolving pandemic.

Based on international experience and various national advisories, social distancing, personal hygiene, using appropriate personal protection equipment (PPE), and isolating the highest risk population (age > 60 years, those with underlying cardiovascular disease or its risk factors such as hypertension and diabetes mellitus, those with medical comorbidities and the immunocompromised patients) are most important in containing and mitigating COVID-19.

1. It is caused by SARS-CoV-2, a single-stranded RNA enveloped virus that binds to ACE2 receptors on lung alveolar cells 3 . These receptors are also present in the heart, vascular endothelium, kidney and the intestines. 2. The SARS-CoV-2 virus is spread via respiratory droplets although there are now reports that the virus can be detected in air under experimental condition for a period up to three hours. Fomites also play a role in transmission with the virus remaining viable in cardboard for 24 hours, on plastic and steel for 3 days. The virus can be detected in faeces and blood although this does not seem to be an important mechanism for spread of the virus 4-6 . 3. The infectivity of COVID-19 is greater than that of the usual influenza virus, with an estimated R 0 value (the basic reproduction number, representing viral infectivity) of 2.2 7 . Overall mortality ranges from 0.25% to as high as 3.0% 8 .

1. Although the virus predominantly affects the respiratory system producing a typical influenza like illness, it also shows affinity for the cardiovascular system. COVID-19 patients with pre-existing cardiovascular disease (CVD) have an increased risk of severe disease and death (case fatality rates of 6% among hypertensives, 7.3% among diabetics and 10.5% with CVD) 9 . Depending upon population studied prevalence of cardiovascular disease ranges from 5-15% 9-12 . 2. Majority of cardiovascular events in patients with COVID -19 infection are the result of severe inflammatory and hemodynamic changes in patients with extensive respiratory involvement. This produces supply-demand mismatch myocardial ischemia due to hypoxia/ hemodynamic instability. These are generally seen in the second week of the illness and may manifest with ECG changes and troponin elevation 9-13 . 3. Some patients can present as myocarditis including a severe fulminant myocarditis due to cytokine storm with regional ST elevation, marked troponin release and ventricular dysfunction 14 . 4. Type I myocardial ischemia due to atherosclerotic plaque instability resulting from direct vascular infection is uncommon. 5. Many patients can present with chest pain, shortness of breath and palpitations secondary to pulmonary involvement. 6. Thus, the range of cardiovascular manifestations of COVID-19 include a. Acute cardiac injury (defined as "Troponin elevations") is common. Type I acute coronary syndrome (ACS) is uncommon. b. Myocarditis and cardiomyopathy including a severe fulminant form due to cytokine storm syndrome with elevations in NT-pro-BNP, troponin and IL-6 levels c. Arrhythmia occurred in 16.7% of patients in a case series from China 12 d. Venous thromboembolism probably due to vascular inflammation and immobilization 11, 15 .

1. Patient Delay: Due to existing situation prevailing in the country, one can expect delays in patient presentation due to lack of transportation, lack of routine medical services at first medical contact or patient's fear of contracting an infection from the healthcare system. At the height of the epidemic treatment delays may also be expected due to limited emergency medical services on account of sick staff or system overload. Mass public education efforts using media will be needed to assure patients that healthcare services remain operational and safe for use 16-18 2. Current non-availability of a rapid nucleic acid test for SARS-CoV-2 infection does not permit rapid discrimination of patients COVID-19 status (Covid-19 positive or negative). Even when available this testing will also cause some delay in providing reperfusion 19 .

results are available only after 24 to 72 hours. 4. Abnormal troponin values are common among those with COVID-19 infection particularly when testing with a high sensitivity cardiac troponin (hs-cTn) assay. This scenario is more commonly due to direct ("non-coronary") myocardial injury (myocarditis) or due to Type 2 myocardial infarction (MI) due to supply-demand imbalance in patients with severe pulmonary disease. Type 1 acute myocardial infarction due to plaque rupture triggered by the infection is uncommon. Therefore Troponins should be measured only if diagnosis of MI is being considered on clinical grounds and disregard casually ordered abnormal troponin value 20,21 . 5. With the anticipated surge, there may be a shortage of appropriate PPE across the country, something already experienced globally 22 . To overcome this scarcity, the US FDA recently granted an Emergency Use Authorization (EUA) for the reuse of the single-use-disposable N-95 respirator, using a vaporized hydrogen peroxide decontamination method 23 . Use of Ethylene Oxide re-sterilization is currently awaiting FDA clearance 24 6. There may be a constant need to reassess the risk-benefit ratio of optimal management strategies for STEMI, weighing in the effect of different stages of the pandemic on hospital preparedness.

1. At the present stage in COVID-19 epidemic, it is imperative to screen every patient for history of (h/o) international travel or contact with a COVID-19 patient and fever with respiratory symptoms, on presentation at the first medical contact. 2. The respiratory status of the patient should be assessed and classified. For instance, the risk-benefit ratio of primary PCI may be limited in patients with severe pneumonia. 3. Patients presenting with Acute MI could be classified into 3 groups (Fig 1) a 25 . However, the reperfusion strategy should be based not only on prevailing logistics and hospital preparedness but also on strategies to reduce nosocomial infection. 9. For the stable NSTEMI patient, coronary angiography and or PCI should be deferred until a COVID-19 negative test has been obtained. 10. For the confirmed or suspected COVID-19 patient, thrombolysis should be given in an isolation room/area within the designated ICCU as per institutional protocol. 11. In small towns and villages and at the spokes in a hub and spoke model of STEMI care, thrombolysis should be the preferred reperfusion strategy. Inter-institutional transfers should be discouraged, and the index facility should be encouraged to stabilize the patient using teleconsultation. (see Fig 1) Preparedness of the Cardiovascular Care Team 1. PROTECT YOURSELF FIRST not only to avoid getting infected, but also to importantly prevent nosocomial infections (other patients and coworkers) as well as community spread of the infection which could ruin the strategy of containing and mitigating the disease. It is reported that 41.3% of the COVID-19 transmission is presumably hospital-related in Wuhan, China 12 . 2. While treating a confirmed or suspected COVID-19 patient, appropriate PPE is paramount as per national/ international advisories. This should include caps, surgical masks, N-95 respirator masks, face shields, eye protection goggles, gowns, gloves and shoe covers. The entire team should review and practise donning and doffing of PPE. Assistance of infection-control trainers should be taken. 3. It is preferable to intubate patients with borderline respiratory status before wheeling these patients into the cardiac catheterization laboratory (CCL). 4. Echocardiogram should be ordered only if it contributes to decision-making. 5. All personal equipment including stethoscopes and cellphones have to be decontaminated. 6. There should be minimal equipment in the CCL during PCI procedure as these will require decontamination after the procedure in a COVID-19 positive patient. 7. As most CCLs are not negative-pressurized rooms, they will need cleaning after procedures on a patient with suspected or confirmed COVID-19 which may prolong turnaround time of the CCL. When there are multiple CCLs in the hospital it would be useful to use a dedicated isolated CCL for such procedures. It will be useful to employ pragmatic approaches that limit both time of exposure as well as the number of health care personnel involved in the care of COVID-19 patients. This may include prescribing once daily medications where feasible, limiting physical examination to essential components only, and providing teleconsultation on follow up 26 . 8. The cardiovascular care team professionals maybe called to be on the front line of the COVID-19 response and therefore should design teams for care of these patients. Health care workers over age 60 years should preferably not be in the front line. 9. Collaborate with others: administrators, intensivists, emergency medicine and infectious disease specialists

The medical management of STEMI remains largely unchanged including antiplatelets, beta blockers, angiotensin converting enzyme inhibitors/ angiotensin receptor blockers, nitrates and statins as indicated. There have been previous reports of lower incidence of COPD and influenza deaths in patients on moderate dose statins, but this remains contentious 27, 28 . Statins should be used as per usual clinical indications. Some of the possible concerns include 1. ACE inhibitors / angiotensin receptor blockers can be safely continued in patients with COVID-19 29,30 .

Chloroquine as well as the anti-retroviral (ARV) drugs Lopinavir/ Ritonavir. Regular monitoring of QT interval is required to minimize risk of torsades de pointes. 3. Being a potent liver enzyme CYP3A4 inhibitor, Lopinavir/Ritonavir also has potential drug interaction with antiplatelets, anticoagulants and statins 26 .

The present COVID-19 pandemic is a medical emergency of an unprecedented scale in recent human history. It has called into question, on a global scale, not only the medical preparedness to handle this contagious disease but has also changed the paradigm for management of everyday procedures. As we continue to handle the onslaught of this pandemic, strategies may continue to evolve 18, 26, 31 . Clinical assessment will be necessary to determine whether a patient with ACS is experiencing a primary coronary event or whether it represents a COVID-19 infection with secondary cardiac involvement. Whenever there is a high suspicion of asymptomatic COVID-19 positive patients in the community, the risk to benefit ratio of primary PCI vs lytic therapy to both the patient as well as hospital personnel will have to be assessed. If hospitals are overwhelmed with COVID -19 patients , the feasibility of timely primary PCI will be a challenge and situation should be dealt in accordance with available resources. CCL preparedness with adequate PPEs will be mandatory for care of COVID-19 patients. Protection of health care workers is paramount so that workforce is not depleted and is available as the pandemic evolves. 

Kishori Ram Hospital & Diabetes Care Centre, India 14. Armed Forces Medical College

Post Graduate Institute of Medical Sciences

University of Miami, Florida, USA References 1. WHO Coronavirus disease (COVID-19) Situation Dashboard

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Aerosol and Surface Stability of SARS CoV-2 as Compared with SARS-CoV-1

Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child

Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Case-fatality Risk estimates for COVID-19 calculated by using a lag iime for fatality. Emerg Infect Dis

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Impact of coronavirus disease 2019(COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China

Circ Cardiovasc Qual Outcomes

American College of Cardiology's (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI)

How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care

Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Troponin and BNP Use in COVID-19

Fair allocation of scarce medical resources

Cardiological Society of India: Position Statement for the management of ST-elevation myocardial infarction in India

Guidance from the CCS COVID-19 Rapid Response Team. COVID-19 and Cardiovascular Disease: What the cardiac health care provider should know

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

Is There a Role For Statin Therapy in Acute Viral Infections

HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. Circulation